The FDA pilot program explores innovative and emerging approaches for the tracing and verification of prescription products
Author Archive: AZBio
Updated Guidance for Arizona Individual Income Taxpayers
The Arizona Department of Revenue issued the following guidance for individual income taxpayers now that the Arizona legislature has determined the matter of conforming to the Internal Revenue Code (IRC).
UA College of Medicine – Phoenix Student Surprised with $25,000 Scholarship from the Arizona Lottery
Dario Alvarez plans a future as a pediatrician to serve underrepresented communities.Continue reading
Helios Scholars at TGen prepares students for success
One intern seeks physician-scientist career after participating in real-life biomedical research at TGenContinue reading
Aqualung Therapeutics Corporation Receives $1.7 Million National Institute of Health (NIH) Fastrack Award
AQUALUNG THERAPEUTICS CORPORATION receives a $1.7 MILLION National Institutes of Health (NIH) Fastrack award to develop a novel immune-based therapeutic anitibody for critically ill patients with acute lung injury.
Arizona at BIO 2019
The BIO International Convention has concluded. Hosted by the Biotechnology Innovation Organization (BIO), this year’s Convention drew 17,307 attendees from 49 states, the District of Columbia, Puerto Rico and 65 countries to Philadelphia and its burgeoning biotech community.Continue reading
Plans for Oro Valley Innovation Lab or OVIL Progresss
A planned Oro Valley biotech incubator has secured additional funding, with Pima County signing on to allocate up to $60,000 for development.
The biotech incubator, Oro Valley Innovation Labs, is intended to add to the growing high-tech industry in Pima County by providing space for nascent businesses to conduct research and product development, with a focus on medical diagnostics.
Read more at Tucson.com: https://tucson.com/business/planned-oro-valley-biotech-incubator-secures-additional-funding/article_556b35e7-6c14-59d2-a0eb-9ef9bc4e0efc.html
OncoMyx Therapeutics Completes $25 Million Series A Financing
PHOENIX, AZ – June 5, 2019 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform from Arizona State University (ASU), announced today the completion of a $25 million series A financing led by Boehringer Ingelheim Venture Fund (BIVF), Delos Capital, and Xeraya Capital with participation from Korea Investment Partners (KIP), City Hill Ventures, and Madison Partners. OncoMyx plans to use the proceeds to advance development of its lead oncolytic virus (OV) therapeutic program for the treatment of various cancers.Continue reading